Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex

References

• SherwoodLMRelative importance of parathyroid hormone and thyrocalcitonin in calcium homeostasisN Engl J Med1968278126636705637251
   PubMedGoogle Scholar
• PooleKEReeveJParathyroid hormone – a bone anabolic and catabolic agentCurr Opin Pharmacol20055661261716181808
   PubMed Web of Science ®Google Scholar
• IshizuyaTYokoseSHoriMParathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cellsJ Clin Invest19979912296129709185520
   PubMedGoogle Scholar
• WatsonPLazowskiDHanVFraherLSteerBHodsmanAParathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized ratsBone19951633573657786639
   PubMedGoogle Scholar
• JilkaRLWeinsteinRSBellidoTRobersonPParfittAMManolagasSCIncreased bone formation by prevention of osteoblast apoptosis with parathyroid hormoneJ Clin Invest1999104443944610449436
   PubMed Web of Science ®Google Scholar
• MaYLCainRLHalladayDLCatabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formationEndocrinology200114294047405411517184
   PubMedGoogle Scholar
• MannstadtMJuppnerHGardellaTJReceptors for PTH and PTHrP: their biological importance and functional propertiesAm J Physiol19992775 pt 2F665F67510564229
   PubMedGoogle Scholar
• RiekAETowlerDAThe pharmacological management of osteoporosisMo Med2011108211812321568234
   PubMedGoogle Scholar
• SaagKGShaneEBoonenSTeriparatide or alendronate in glucocorticoid-induced osteoporosisN Engl J Med2007357202028203918003959
   PubMed Web of Science ®Google Scholar
• Teriparatide (forteo) for osteoporosisMed Lett Drugs Ther200345114991012571538
   PubMedGoogle Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• EttingerBBlackDMMitlakBHReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA1999282763764510517716
   PubMed Web of Science ®Google Scholar
• ChesnutCH3rdSilvermanSAndrianoKA randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study GroupAm J Med2000109426727610996576
   PubMed Web of Science ®Google Scholar
• HammerleSPMindeholmLLaunonenAThe single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal womenBone201250496597322289659
   PubMed Web of Science ®Google Scholar
• LaneNESilvermanSLAnabolic therapiesCurr Osteoporos Rep201081232720425087
   PubMedGoogle Scholar
• MatsumotoTShirakiMHaginoHIinumaHNakamuraTDaily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot studyOsteoporos Int200617101532153816767525
   PubMed Web of Science ®Google Scholar
• GoldbergMGomez-OrellanaIChallenges for the oral delivery of macromoleculesNat Rev Drug Discov20032428929512669028
   PubMed Web of Science ®Google Scholar
• WoodleyJFEnzymatic barriers for GI peptide and protein deliveryCrit Rev Ther Drug Carrier Syst1994112–361957600588
   PubMed Web of Science ®Google Scholar
• Leone-BayASatoMPatonDOral delivery of biologically active parathyroid hormonePharm Res200118796497011496956
   PubMed Web of Science ®Google Scholar
• NarayananDAnithaAJayakumarRNairSVChennazhiKPSynthesis, characterization and preliminary in vitro evaluation of PTH 1-34 loaded chitosan nanoparticles for osteoporosisJ Biomed Nanotechnol2012819810622515098
   PubMed Web of Science ®Google Scholar
• NarayananDAnithaAJayakumarRChennazhiKPIn vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticlesMol Pharm201310114159416724006937
   PubMed Web of Science ®Google Scholar
• JeonOCSeoDHKimHSByunYParkJWOral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: in vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized ratsEur J Pharm Sci20168211026542347
   PubMed Web of Science ®Google Scholar
• ParkJWHwangSRJeonOCMoonHTByunYEnhanced oral absorption of ibandronate via complex formation with bile acid derivativeJ Pharm Sci2013102234134623233267
   PubMedGoogle Scholar
• HubatschIRagnarssonEGArturssonPDetermination of drug permeability and prediction of drug absorption in Caco-2 monolayersNat Protoc2007292111211917853866
   PubMed Web of Science ®Google Scholar
• VoglerGAAnesthesia and analgesiaSuckowMAWeisbrothSHFranklinCLThe Laboratory Rat2nd edMassachusettsElsevier Academic Press2006627664
   Google Scholar
• YeoYParkKA new microencapsulation method using an ultrasonic atomizer based on interfacial solvent exchangeJ Control Release2004100337938815567503
   PubMed Web of Science ®Google Scholar
• PerilliELeVMaBSalmonPReynoldsKFazzalariNLDetecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated ratsOsteoporos Int20102181371138219809776
   PubMedGoogle Scholar
• CohenFEStrewlerGJBradleyMSAnalogues of parathyroid hormone modified at positions 3 and 6. Effects on receptor binding and activation of adenylyl cyclase in kidney and boneJ Biol Chem19912663199720041846369
   PubMedGoogle Scholar
• GuptaVHwangBHLeeJAnselmoACDoshiNMitragotriSMucoadhesive intestinal devices for oral delivery of salmon calcitoninJ Control Release2013172375376224035976
   PubMed Web of Science ®Google Scholar
• AdamiSPasseriMOrtolaniSEffects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosisBone19951743833908573412
   PubMed Web of Science ®Google Scholar
• DempsterDWBologneseMAIbandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosisJ Clin Densitom200691586516731432
   PubMedGoogle Scholar
• ParkJWKimSJKwagDSMultifunctional delivery systems for advanced oral uptake of peptide/protein drugsCurr Pharm Des201521223097311026027575
   PubMed Web of Science ®Google Scholar
• AmidonGLLeeHJAbsorption of peptide and peptidomimetic drugsAnnu Rev Pharmacol Toxicol1994343213418042854
   PubMed Web of Science ®Google Scholar
• VaraminiPTothIRecent advances in oral delivery of peptide hormonesExpert Opin Drug Deliv201613450752226787260
   PubMed Web of Science ®Google Scholar
• SchatzGDobbersteinBCommon principles of protein translocation across membranesScience19962715255151915268599107
   PubMed Web of Science ®Google Scholar
• HofmannAFMyselsKJBile salts as biological surfactantsColloids Surf1987301145173
   Google Scholar
• AungstBJIntestinal permeation enhancersJ Pharm Sci200089442944210737905
   PubMed Web of Science ®Google Scholar
• MahmudFJeonOCAl-HilalTAAbsorption mechanism of a physical complex of monomeric insulin and deoxycholyl-l-lysyl-methylester in the small intestineMol Pharm20151261911192025892399
   PubMedGoogle Scholar
• JeonOCHwangSRAl-HilalTAOral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primatesPharm Res201330495996723292220
   PubMed Web of Science ®Google Scholar
• Al-HilalTAParkJAlamFOligomeric bile acid-mediated oral delivery of low molecular weight heparinJ Control Release2014175172424333628
   PubMed Web of Science ®Google Scholar
• FreemanMWWirenKMRapoportALazarMPottsJTJrKronenbergHMConsequences of amino-terminal deletions of preproparathyroid hormone signal sequenceMol Endocrinol1987196286383153480
   PubMedGoogle Scholar
• BardenJAKempBENMR solution structure of human parathyroid hormone(1-34)Biochemistry19933228712671328343504
   PubMedGoogle Scholar
• Abou-SamraABJuppnerHForceTExpression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calciumProc Natl Acad Sci U S A1992897273227361313566
   PubMed Web of Science ®Google Scholar
• Gesty-PalmerDLuttrellLM‘Biasing’ the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?Br J Pharmacol20111641596721506957
   PubMedGoogle Scholar
• WerleMSamhaberABernkop-SchnürchADegradation of teriparatide by gastro-intestinal proteolytic enzymesJ Drug Target200614310911516753824
   PubMed Web of Science ®Google Scholar
• ParkJHYeMYeoYLeeWKPaulCParkKReservoir-type microcapsules prepared by the solvent exchange method: effect of formulation parameters on microencapsulation of lysozymeMol Pharm20063213514316579642
   PubMedGoogle Scholar
• XieJNgWJLeeLYWangCHEncapsulation of protein drugs in biodegradable microparticles by co-axial electrosprayJ Colloid Interface Sci2008317246947617945246
   PubMed Web of Science ®Google Scholar
• YeoYBasaranOAParkKA new process for making reservoir-type microcapsules using ink-jet technology and interfacial phase separationJ Control Release200393216117314636722
   PubMed Web of Science ®Google Scholar
• DalmoroABarbaAALambertiGd’AmoreMIntensifying the microencapsulation process: ultrasonic atomization as an innovative approachEur J Pharm Biopharm201280347147722285525
   PubMed Web of Science ®Google Scholar
• WenYGallegoMRNielsenLFJorgensenLMollerEHNielsenHMDesign and characterization of core-shell mPEG-PLGA composite microparticles for development of cell-scaffold constructsEur J Pharm Biopharm2013851879823958320
   PubMed Web of Science ®Google Scholar
• RixonRHWhitfieldJFGagnonLParathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclaseJ Bone Miner Res199498117911897976500
   PubMedGoogle Scholar
• WronskiTJDannLMScottKSCintronMLong-term effects of ovariectomy and aging on the rat skeletonCalcif Tissue Int19894563603662509027
   PubMed Web of Science ®Google Scholar
• GenantHKCooperCPoorGInterim report and recommendations of the World Health Organization task-force for osteoporosisOsteoporos Int199910425926410692972
   PubMed Web of Science ®Google Scholar
• MüllerRHahnMVogelMDellingGRüegseggerPMorphometric analysis of noninvasively assessed bone biopsies: comparison of high-resolution computed tomography and histologic sectionsBone19961832152208703575
   PubMedGoogle Scholar
• HildebrandTLaibAMullerRDequekerJRuegseggerPDirect three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneusJ Bone Miner Res19991471167117410404017
   PubMed Web of Science ®Google Scholar
• JeromeCPBurrDBVan BibberTHockJMBrommageRTreatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)Bone200128215015911182372
   PubMedGoogle Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar